Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 11

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 11
---
 and, if applicable, the conversion price 
 (or how it will be calculated) and conversion period;                                                           |

6

| • |     | whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or 
 how it will be calculated) and exchange period;                                                                   |

| • |     | voting rights, if any, of the preferred stock; |

| • |     | a discussion of any material U.S. federal income tax considerations applicable to the preferred stock; |

| • |     | the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, 
 dissolution or winding up of the affairs of the Company; and                                                   |

| • |     | any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity                 
 with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the Company. |

The preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights. Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law Certain provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, encourage persons seeking to acquire control of us to first negotiate with our board of directors and the holders of our capital stock. Delaware Law We are subject to Section 203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for three years following the date that the stockholder became an interested stockholder, unless:

| • |     | prior to the date of the transaction, the board of directors of the corporation approved either the business 
 combination or the transaction which resulted in the stockholder becoming an interested stockholder;         |

| • |     | upon completion of the transaction that resulted in the interested stockholder becoming an interested                                                                                                                                              
 stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by    
 persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be